Literature DB >> 12865270

Ten year follow up of ulcerative colitis patients with and without low grade dysplasia.

C H Lim1, M F Dixon, A Vail, D Forman, D A F Lynch, A T R Axon.   

Abstract

BACKGROUND AND AIMS: Low grade dysplasia (LGD) is believed to predispose to colorectal cancer (CRC), and proctocolectomy has been advocated when this is identified. Between 1978 and 1990, 160 patients with longstanding extensive ulcerative colitis (UC) were recruited for annual colonoscopic surveillance and 40 developed LGD at some stage. We report the outcome of this cohort 10 years after the original study ended.
METHODS: Retrospective cohort study and histopathological review of the original diagnoses of LGD. The outcome of 158/160 (98.8%) patients was established in 2000.
RESULTS: Of the 128 patients still alive and with an intact colon at the end of 1990, two were not traceable, 29 had LGD, and 97 had no dysplasia (controls). After 10 years, high grade dysplasia (HGD) or CRC developed in 3/29 LGD (10%) and in 4/97 controls (4.0%). Kaplan-Meier analysis from 1991 to death or colectomy did not show a statistically significant difference between the two groups (log rank test p=0.63). Histopathological review demonstrated the unreliability of LGD diagnosis. Agreement between pathologists was uniformly poor: kappa <0.4 for all comparisons.
CONCLUSION: LGD diagnosis is not sufficiently reliable to justify prophylactic colectomy. Conservative management of established LGD cases should not be ruled out.

Entities:  

Mesh:

Year:  2003        PMID: 12865270      PMCID: PMC1773763          DOI: 10.1136/gut.52.8.1127

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  31 in total

1.  Guidelines for screening and surveillance of asymptomatic colorectal cancer in patients with inflammatory bowel disease.

Authors:  J A Eaden; J F Mayberry
Journal:  Gut       Date:  2002-10       Impact factor: 23.059

2.  Ulcerative colitis. Cancer surveillance in an unselected population.

Authors:  J Rutegård; L Ahsgren; R Stenling; K G Janunger
Journal:  Scand J Gastroenterol       Date:  1988-03       Impact factor: 2.423

3.  On calculating cancer risk and survival of ulcerative colitis patients with the life table method.

Authors:  G Devroede; W F Taylor
Journal:  Gastroenterology       Date:  1976-09       Impact factor: 22.682

4.  The fate of low grade dysplasia in ulcerative colitis.

Authors:  Thomas A Ullman; Edward V Loftus; Sanjay Kakar; Lawrence J Burgart; William J Sandborn; William J Tremaine
Journal:  Am J Gastroenterol       Date:  2002-04       Impact factor: 10.864

5.  Rectal biopsy as an aid to cancer control in ulcerative colitis.

Authors:  B C Morson; L S Pang
Journal:  Gut       Date:  1967-10       Impact factor: 23.059

6.  Rectal biopsy and precancer in ulcerative colitis.

Authors:  H E Myrvold; N G Kock; C Ahrén
Journal:  Gut       Date:  1974-04       Impact factor: 23.059

7.  Dysplasia-associated lesion or mass (DALM) detected by colonoscopy in long-standing ulcerative colitis: an indication for colectomy.

Authors:  M O Blackstone; R H Riddell; B H Rogers; B Levin
Journal:  Gastroenterology       Date:  1981-02       Impact factor: 22.682

8.  Cancer in universal and left-sided ulcerative colitis: factors determining risk.

Authors:  A J Greenstein; D B Sachar; H Smith; A Pucillo; A E Papatestas; I Kreel; S A Geller; H D Janowitz; A H Aufses
Journal:  Gastroenterology       Date:  1979-08       Impact factor: 22.682

9.  Cancer surveillance of patients with longstanding ulcerative colitis: a clinical, endoscopical, and histological study.

Authors:  O Broström; R Löfberg; A Ost; H Reichard
Journal:  Gut       Date:  1986-12       Impact factor: 23.059

10.  Cancer surveillance in ulcerative colitis. Experience over 15 years.

Authors:  J E Lennard-Jones; B C Morson; J K Ritchie; C B Williams
Journal:  Lancet       Date:  1983-07-16       Impact factor: 79.321

View more
  41 in total

Review 1.  Gastroenterology services in the UK. The burden of disease, and the organisation and delivery of services for gastrointestinal and liver disorders: a review of the evidence.

Authors:  J G Williams; S E Roberts; M F Ali; W Y Cheung; D R Cohen; G Demery; A Edwards; M Greer; M D Hellier; H A Hutchings; B Ip; M F Longo; I T Russell; H A Snooks; J C Williams
Journal:  Gut       Date:  2007-02       Impact factor: 23.059

Review 2.  Inflammatory bowel disease: the problems of dysplasia and surveillance.

Authors:  P J Mitchell; E Salmo; N Y Haboubi
Journal:  Tech Coloproctol       Date:  2007-11-30       Impact factor: 3.781

Review 3.  Dysplasia and colitis.

Authors:  Robert Enns; Brian Bressler
Journal:  Can J Gastroenterol       Date:  2009-05       Impact factor: 3.522

Review 4.  Colorectal cancer in inflammatory bowel disease: what is the real magnitude of the risk?

Authors:  Jessica K Dyson; Matthew D Rutter
Journal:  World J Gastroenterol       Date:  2012-08-07       Impact factor: 5.742

5.  Current management of inflammatory bowel disease and colorectal cancer.

Authors:  Mark C Mattar; Denver Lough; Michael J Pishvaian; Aline Charabaty
Journal:  Gastrointest Cancer Res       Date:  2011-03

Review 6.  Cancer risk in IBD: how to diagnose and how to manage DALM and ALM.

Authors:  Helmut Neumann; Michael Vieth; Cord Langner; Markus F Neurath; Jonas Mudter
Journal:  World J Gastroenterol       Date:  2011-07-21       Impact factor: 5.742

Review 7.  Colonic crohn disease.

Authors:  Traci L Hedrick; Charles M Friel
Journal:  Clin Colon Rectal Surg       Date:  2013-06

8.  Accomplishments in 2008 in biologic markers for gastrointestinal cancers-focus on colorectal cancer.

Authors:  Sabine Tejpar; Robert D Odze
Journal:  Gastrointest Cancer Res       Date:  2009-09

Review 9.  Cancer in inflammatory bowel disease.

Authors:  Jianlin Xie; Steven H Itzkowitz
Journal:  World J Gastroenterol       Date:  2008-01-21       Impact factor: 5.742

10.  [Intraepithelial neoplasia/dysplasia - histopathology in ulcerative colitis].

Authors:  G B Baretton; D E Aust
Journal:  Pathologe       Date:  2008-11       Impact factor: 1.011

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.